
Diabetes
A short sentence to introduce what to expect in the about condition
section
Learn more
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection for Phase 3.





The prescreener preview is complete. You may now close the preview.
